« Previous Page: 1 of 9 Next »

Announcements Stay up to date.  Click here to subscribe to the Announcements RSS Feed

Changes to USMLE procedures for reporting scores

Posted: May 04, 2011

Starting July 1, 2011, USMLE transcripts reported through the ERAS reporting system will no longer include score results on the 2-digit score scale. USMLE results will continue to be reported on the 3-digit scale. This affects the Step 1, 2 CK, and 3 examinations only; Step 2 CS will continue to be reported as pass or fail. These changes do not alter the score required to pass or the difficulty of any of the USMLE Step examinations.

Since its beginning in the 1990s, the USMLE program has reported two numeric scores for the Step 1, Step 2 CK, and Step 3 examinations, one on a 3-digit scale and one on a 2-digit scale. The 3-digit score scale is considered the primary reporting scale; it is developed in a manner that allows reasonable comparisons across time. The 2-digit scale is intended to meet statutory requirements of some state medical boards that rely on a score scale that has 75 as the minimum passing score.  The process used to convert 3-digit scores to 2-digit scores is designed in such a way that the 3-digit minimum passing score in effect when the examinee tests is associated with a 2-digit score of 75.

The USMLE program requires its governing committees to reevaluate the minimum passing score every three to four years. This process has, at times, resulted in changes in the minimum passing score, expressed on the 3-digit scale, and an accompanying change in the score conversion process, to ensure that a 2-digit score of 75 is associated with the new minimum passing requirement. A by-product of the adjustment of the score conversion system over time has been a shift in the relationship between the two score scales. This shift has no impact for USMLE score users who use the 3-digit scoring scale or for those using the 2-digit scale with a primary interest in whether the examinee has a passing 2-digit score of at least 75. However, it may create challenges in interpretation for score users who are focusing on 2-digit scores, other than 75, and are doing so for purposes of comparing USMLE scores that span several years.

To simplify matters and make interpretation of USMLE information more convenient for score users, the USMLE Composite Committee has asked staff to report 2-digit scores only to those score users for whom the scale is intended, i.e., the state medical boards. The Committee also asked that examinees continue to receive scores on both scales so that they are fully informed about the information that will be reported when they ask that results be sent to a state medical board. When examinees request that their results be sent to other score users, only the 3-digit score will be reported. Current plans call for these changes to begin with the elimination of the 2-digit score from USMLE transcripts reported through the ERAS reporting system starting July 1, 2011. Other systems and procedures for reporting results will be similarly modified as soon as possible after the July 1, 2011 date.

Computer-Based Case Simulations (CCS) Field Trial

Posted: August 17, 2015
Updated: September 19, 2015

The National Board of Medical Examiners® (NBME®) has developed new software to deliver the Primum® Computer-based Case Simulations (CCS) component of Step 3 of the United States Medical Licensing Examination® (USMLE®), which is jointly owned by the NBME and the Federation of State Medical Boards. The new software incorporates user-adjustable display features, specifically text magnification and reverse color (color inversion).

NBME is planning a field trial of the software from November 16, 2015 through February 29, 2016 at select Prometric test centers in the United States. NBME is seeking medical students and graduates with varying levels of visual ability (with or without visual impairments) to participate in the field trial.

Individuals who anticipate taking USMLE Step 3 at a future date may find participation useful. The field trial will include some cases not currently available as Step 3 CCS practice cases on the USMLE website.


  • Each participant who completes all sections of the field trial, including the end-of-exam survey, will receive a $50 honorarium approximately two weeks after the field trial ends; this timeline is subject to change.
  • There are no fees associated with participation in the field trial.
  • Performance on the field trial will be strictly confidential. Score reports will NOT be provided to participants nor reported to any third party.
  • Results of the Primum CCS field trial cannot be substituted for USMLE Step scores for the purpose of medical licensure in the United States nor for meeting the requirements for a United States H-1B visa.


November 16, 2015 to February 29, 2016


The Primum CCS field trial is a half-day (3-hour, 36-minute) exam. The testing day will be divided into the following components:

  • 15-minute tutorial1
  • Five 21-minute blocks, each containing one 20-minute case
  • Six 11-minute blocks, each containing one 10-minute case
  • One 20-minute block with CCS feedback2
  • 10 minutes total break time (to be taken between blocks)

1 It is highly recommended that participants practice with the Primum CCS software before the field trial, becoming familiar with both the software interface and background information. Click here to review the orientation material and practice with sample cases. The software in the field trial will be a new version with enhanced usability features, and therefore, different from the current software interface available on the USMLE website. Nonetheless, it will be beneficial to practice with the existing software interface in advance of the field trial.

2 This block includes feedback on diagnostic and management steps for the sample Step 3 CCS cases. The CCS database contains thousands of possible tests and treatments. Therefore, it is not feasible to list every action that might affect an examinee's score. The descriptions are meant to serve as examples of actions that would add to, subtract from, or have no effect on an examinee's score for each case.


Click here to see a list of all field trial test center locations. 

* Test center locations are subject to change


  • No additional applications are being accepted.
  • The deadline for submitting applications was September 18, 2015 at 11:59 pm Eastern Time in the United States.


After the application deadline, the NBME will use stratified random sampling to select participants from the pool of applicants. Only one application per person will be considered in the selection pool; duplicates will be excluded.

Those selected to participate will receive e-mail notifications and electronic scheduling permits (e-permits), which will provide instructions for scheduling appointments. Applicants who have not been selected will also be notified by e-mail. The NBME plans to send notification e-mails on or around October 5, 2015.

Please note that e-permits and other communications will be sent to the e-mail address you enter into the online application. Therefore, it is very important that you check your information for accuracy prior to submitting the application.

Those applying to participate in this field trial acknowledge that they have read, understood, and agreed to be bound by the provisions contained in this announcement. Those who do not wish to be bound by these provisions should not apply.

  • Due to the limited duration of the field trial, rescheduling may not be possible if a participant’s plans change.
  • A participant who fails to appear for a scheduled appointment cannot request another appointment.
  • A major purpose of the field trial is to test the enhanced functionality of the Primum CCS Software. There is no guarantee that a participant will be able to start, or complete, any or all sections of the field trial. Rescheduling will not be possible if technical difficulties occur that prevent the start or completion of the trial at a test center. However, if a participant is unable to complete the field trial due to technical difficulties, the full $50 honorarium will be provided.
  • Participation in the field trial is free. However, any associated costs (e.g., travel, meals) are the responsibility of the individual participant.
  • Under no circumstances shall the NBME be liable for any damages or costs that may result in any way from participation in the field trial or from a participant’s use of the information derived from participation in the field trial.

New Features

Two new user-adjustable display features will be piloted:

  • Reverse color (color inversion)
  • Text magnification

The new display features are NOT currently available on live USMLE administrations or in practice materials available on the USMLE website.

Examinees are encouraged but not required to use the new features; they will not interfere with an examinee’s practice experience. Examinees will be asked to complete a brief post-session survey about their experience, which will help USMLE determine whether examinees like the new features.

If the features become available in the future for use in USMLE Step examinations or the online practice materials, examinees will be notified well in advance.

Reverse color
Inverts the color of the text and background from black-on-white to white-on-black. The ability to reverse color (also known as color inversion) improves readability for some users.

Screen capture: reverse color

Text magnification

Two levels of text magnification will be available.

Screen capture: text magnification, before
Screen capture: text magnification, after


    The NBME is providing the materials presented in this field trial for personal use only. The materials are owned and copyrighted by the NBME or jointly by the FSMB and the NBME. The materials may not be transferred or reproduced in any way. Any unauthorized reproduction of these materials, by any means, including but not limited to, copying or printing of electronic files, reconstruction through memorization and/or dictation, and/or dissemination of these materials or any part of them is strictly prohibited.


    Questions about this field trial may be directed to fieldtrial@nbme.org

Review of USMLE Step 3 minimum passing performance

Posted: September 09, 2015

The USMLE program recommends a minimum passing level for each Step examination. The USMLE Management Committee is responsible for establishing and monitoring these standards, and is asked to complete an in-depth review of standards for each examination every three to four years.

For the 2015 Step 3 review, information from multiple sources will be considered, including:

  • Results of content-based standard setting exercises conducted with three independent groups of physicians in 2015;
  • Results of surveys of various groups (e.g., state licensing representatives, medical school faculty, samples of examinees) concerning the appropriateness of current pass/fail standards for Step examinations;
  • Trends in examinee performance;
  • Score precision and its effect on the pass/fail outcome.

The USMLE Management Committee is scheduled to review the minimum passing score for the USMLE Step 3 examination at its meeting on December 9-10, 2015.

If the Committee determines that a change to the minimum passing score is appropriate, the new recommended minimum passing score will become effective for all examinees who take a Step 3 examination on or after January 1, 2016. The decision of the Committee will be posted at the USMLE website.

« Previous Page: 1 of 9 Next »